PMID- 36404200
OWN - NLM
STAT- MEDLINE
DCOM- 20221206
LR  - 20240102
IS  - 1424-3911 (Electronic)
IS  - 1424-3903 (Linking)
VI  - 22
IP  - 8
DP  - 2022 Dec
TI  - The efficacy and safety of modified FOLFIRINOX for unresectable advanced 
      pancreatic cancer in elderly versus young patients: A multicenter retrospective 
      cohort study.
PG  - 1134-1140
LID - S1424-3903(22)00792-X [pii]
LID - 10.1016/j.pan.2022.11.005 [doi]
AB  - In the treatment of advanced pancreatic cancer (APC), FOLFIRINOX (FX), including 
      its dose-modified regimen (mFX), is considered an effective regimen; however, FX 
      is also known to be associated with a high incidence of adverse events due to its 
      multi-agent combination regimen. The efficacy and safety in elderly patients with 
      APC have not been well studied. AIM: To compare the safety and efficacy of 
      first-line mFX for unresectable APC in elderly and young patients. METHODS: This 
      was a multicenter retrospective cohort study included patients who received 
      first-line mFX for unresectable APC. A total of 151 patients were included and 
      divided into the elderly (>/=65 years old; 76 patients) and young (<65 years old; 
      75 patients) groups. The primary endpoint was overall survival (OS). The 
      secondary endpoints were progression-free survival (PFS) and adverse events 
      (AEs). RESULTS: The median OS and PFS were similar between the two groups (OS: 
      14.4 months versus 13.9 months, p = 0.42; PFS: 7.4 months versus 6.6 months, 
      p = 0.65). Although severe AEs (>/= grade 3) were observed frequently in both 
      groups (80% versus 84.2%, p = 0.53), there was no significant difference in any 
      of the events between the groups. In the multivariate analysis evaluating the 
      factors affecting OS and febrile neutropenia, age was not significant factors in 
      both analyses. CONCLUSION: First-line mFX for APC in elderly patients was as safe 
      and effective as in younger patients if performance status was good. Further 
      evaluation in a larger cohort is required to confirm our findings.
CI  - Copyright (c) 2022 IAP and EPC. Published by Elsevier B.V. All rights reserved.
FAU - Tezuka, Ryuichi
AU  - Tezuka R
AD  - First Department of Internal Medicine, Gifu University Hospital, Gifu, Japan.
FAU - Iwashita, Takuji
AU  - Iwashita T
AD  - First Department of Internal Medicine, Gifu University Hospital, Gifu, Japan. 
      Electronic address: takuji@w7.dion.ne.jp.
FAU - Uemura, Shinya
AU  - Uemura S
AD  - First Department of Internal Medicine, Gifu University Hospital, Gifu, Japan.
FAU - Senju, Akihiko
AU  - Senju A
AD  - First Department of Internal Medicine, Gifu University Hospital, Gifu, Japan.
FAU - Yoshida, Kensaku
AU  - Yoshida K
AD  - Department of Gastroenterology, Gifu Prefectural General Medical Center, Gifu, 
      Japan.
FAU - Maruta, Akinori
AU  - Maruta A
AD  - Department of Gastroenterology, Gifu Prefectural General Medical Center, Gifu, 
      Japan.
FAU - Iwata, Keisuke
AU  - Iwata K
AD  - Department of Gastroenterology, Gifu Municipal Hospital, Gifu, Japan.
FAU - Shimizu, Masahito
AU  - Shimizu M
AD  - First Department of Internal Medicine, Gifu University Hospital, Gifu, Japan.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20221112
PL  - Switzerland
TA  - Pancreatology
JT  - Pancreatology : official journal of the International Association of 
      Pancreatology (IAP) ... [et al.]
JID - 100966936
RN  - 0 (folfirinox)
SB  - IM
MH  - Aged
MH  - Humans
MH  - *Pancreatic Neoplasms/drug therapy
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Chemotherapy
OT  - Ductal adenocarcinoma
OT  - Nab-paclitaxel
OT  - Naive
OT  - Old
COIS- Declaration of competing interest Ryuichi Tezuka, Takuji Iwashita, Shinya Uemura, 
      Akihiko Senju, Kensaku Yoshida, Akinori Maruta, Keisuke Iwata, and Shimizu 
      Masahito have no conflict of interest related to this article.
EDAT- 2022/11/21 06:00
MHDA- 2022/12/07 06:00
CRDT- 2022/11/20 22:05
PHST- 2022/07/02 00:00 [received]
PHST- 2022/10/16 00:00 [revised]
PHST- 2022/11/07 00:00 [accepted]
PHST- 2022/11/21 06:00 [pubmed]
PHST- 2022/12/07 06:00 [medline]
PHST- 2022/11/20 22:05 [entrez]
AID - S1424-3903(22)00792-X [pii]
AID - 10.1016/j.pan.2022.11.005 [doi]
PST - ppublish
SO  - Pancreatology. 2022 Dec;22(8):1134-1140. doi: 10.1016/j.pan.2022.11.005. Epub 
      2022 Nov 12.